RSS
Healthcare: Sales of pharma increased in Q1 by 10.7%
The value of pharma release to the patients in Romania in Q1 of the year, was of 3.27 billion lei, at distribution price, up by 10.7% against 2014, according to the results of the study Pharmaand Hospital Report, made by Cegedim.
'The evolution of Q1 2015 although under that of Q4 2014, was over the expectations due to the performance of OTC (pharma released without prescription) especially the seasonal ones, and paradoxically, due to the announcement of price reduction and health card introduction. Under these conditions, due to the reduction of prices announced recently, for 2015 we revise the evolution of the market prognosis from +/- 3.5% at -2.8% in lei ( after an evaluation on which we come back) but we draw the attention on the drop of the availability of cheap drugs in the second part of the year' said in a press release Petru Craciun, general manager of Cegedim.
Over the counter pharma reached a value of 0.63 billion lei, up by 27% and the hospital segment reached 0.38 billion lei, up by 11.5% against Q1 of the previous year.
As compared to the evolution of the last five quarters, in Q1 of 2015 there is a trend of coming back by stages of positive growth, both in units 12.4% and in days of treatment -10.7% as well as in value in lei or in euro.12.0%.
At the level of the last 12 months, the total value of the market was 12.6 billion lei,up by 10% against the corresponding period of the previous year (April 2013 – March 2014).
Per segments, the growth stages in RON were 7.4% for Rx in drugstores, 20.6% f.or OTC and 11.7% for hospitals.
According to the study, as regards the evolution of the main therapeutic groups, over the last 12 months there has been an increase in volume over the average of the market in the case of drugs for the respiratory system (15.3%) for blood and hematopoetic organs (14.4%) and for the digestive system and metabolism.
As value, the increase of the drugs for the respiratory system was 18.8% for the digestive system and metabolism was 14.3% and for blood and hematopoetic organs 12.2%.
The main 10 corporations as regards the value for the last 12 months is not modified by comparison to the previous quarter, the first being Sanofi (including Zentiva) with 862.8 million lei followed by Hoffmann La Roche with sales of 801.7 million lei and Servier (including Egis) with 705.4 million lei.
The top of the first 10 players is completed by Novartis (including Sandoz) with 698.6 million lei, Pfizer (622.3 million lei) GlaxoSmithKline (553.8 million lei), Ranbaxy (542.4 million lei), AstraZeneca (527.6 million lei) Merck&Co (396.7million) and Krka with 383.5 million lei.
In volumes, the main 10 corporations for the last 12 months do not modify by comparison to the previous quarter, first being Sanofy (including Zentiva) with 62 million units, followed by Ranbaxy/Sun pharma (including Terapia) with 49.5 million units and Servier (including Egis) with 33 million units.
The top of the first 10 players is completed by Alvogen (including Labormed) with 30.7 million units, Antibiotice (30.1 million units) GlaxoSmithKline with 27 million units, Novartis with 26.5 million units, Krka with 23.8 million units, Biofarm with 20.3 million units and Gedeon Richter with 20.2 million units.
Pharma and Hospital Report is made in Romania starting with 1996.
Set up in 1969, Cegedim is a global group of techonology and services in the domain of health care.
Cegedim offers services, technology, specialized applications and data bases to the professionals in health care and the insurance companies. Cegedim has over 3,500 employees in 11 countries and made a turnover of 494 million euro in 2014.Cegedim SA is listed on the Paris Stock Exchange.